ALKSAlkermes plc

1. Sep 21, 2026On September 21, 2026, the Company announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the Company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD).Regulation FD disclosure · Form 8-K
2. Sep 16, 2026On September 14, 2026, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company’s 2027 annual general meeting of …Director or officer change · Form 8-K
3. Aug 12, 2026Term Loan Credit Facilities On August 12, 2026, Alkermes plc (the “Company”) entered into Amendment No. 1 to Credit Agreement (the “Amendment”), which amends the Credit Agreement, dated as of February 12, 2026 (the “Credit Agreement”), among the Company, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower …Material agreement entered · Form 8-K
4. Jul 28, 2026Sandy Coombs +1 781 609 6377.Earnings release · press release
5. Jul 8, 2026On July 6, 2026, Alkermes plc (the “Company”) and Amneal Pharmaceuticals LLC (“Amneal”) terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025 (the “Agreement”)Material agreement terminated · Form 8-K
6. Jun 15, 2026On June 15, 2026, the Company announced that the U.S. Food and Drug Administration has granted orphan drug designation to alixorexton for the treatment of idiopathic hypersomnia, and the European Commission has granted orphan drug designation to alixorexton for the treatment of narcolepsy.Regulation FD disclosure · Form 8-K
7. May 20, 2026On May 20, 2026, at the 2026 annual general meeting of shareholders (the “Annual Meeting”) of Alkermes plc (the “Company”), the Company’s shareholders approved amendments to the Alkermes plc 2018 Stock Option and Incentive Plan to, among other things, increase the number of the Company’s ordinary shares authorized for …Director or officer change · Form 8-K
8. May 12, 2026On May 12, 2026, the Company announced positive topline results from REVITALYZ SM, a double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ ® (sodium oxybate) extended-release oral suspension compared to placebo in adults with idiopathic …Regulation FD disclosure · Form 8-K
9. May 5, 2026Sandy Coombs +1 781 609 6377.Earnings release · press release
10. May 1, 2026Consolidated Financial Statements.Material event (exhibits only) · press release
11. Feb 25, 2026On February 24, 2026, Richard F. Pops, Chairman and Chief Executive Officer of Alkermes plc (the “Company”), notified the Company’s board of directors (the “Board”) of his decision to retire from his position of Chief Executive Officer, effective July 31, 2026, following a distinguished 35 years of service in this role.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.